Small MoleculesJan 28, 2026
Impurity Identification and Structure Elucidation in Drug Development: Case Studies
In this webinar presentation, we will share several cases of identification and structure elucidation in drug development. In the first case, we will discuss how we identify and control a potential genotoxic impurity (PGI) during process optimization of the production of an API. We will also share the identification and structure elucidation of an impurity in a drug product. Finally, we will explain how we use high resolution 2D NMR techniques to characterize a complex peptide-type of structure.
Small MoleculesJan 06, 2026
Impurity Identification in API Analytical Research
During the analytical R&D and quality studies of Active Pharmaceutical Ingredients (APIs), the identification and control of unknown impurities is a critical step for ensuring drug safety.This webinar will share practical strategies for high-efficiency impurity purification and share the experience of the efficient separation and precise preparation of impurities from complex matrices using effective modern chromatographic techniques (e.g., HPLC).
Small MoleculesSep 17, 2025
Molecular Simulation and Data Science Support of Porton
The rapid advancements in computational material science and process simulation have made computational methods indispensable in modern drug development and manufacturing workflows. These approaches enable more efficient navigation through the multidimensional complexities of pharmaceutical process development. By integrating computational and experimental methodologies, we can significantly de-risk pharmaceutical development while achieving substantial time and cost efficiencies. Among these techniques, molecular modeling and data science have emerged as particularly powerful tools—offering a rational, evidence-based framework to guide drug development workflows, as highlighted in recent publications. This structured approach allows researchers to prioritize the most promising solutions for targeted experimental validation, thereby optimizing resource allocation.We are truly privileged to welcome today's speaker: Dr. Yuriy Abramov, Executive Director of Computational Chemistry & Data Science at Porton J-STAR. In this session, he will deliver an expert analysis of computational chemistry and data science strategies designed to streamline drug development and reduce costs.
